Ring Therapeutics has announced strategic partnerships with Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI). These collaborations aim to enhance research and development (R&D) efforts and strengthen the biomedical science ecosystem in the region.The partnerships will support various aspects of Ring Therapeutics' platform, including early discovery initiatives focused on characterising new anellovirus genomes for use in ophthalmology and oncology. Additionally, the collaborations will help expand the company's indication portfolio by testing innovative payloads across different therapeutic areas and improving the performance of its next-generation manufacturing processes.A*STAR and SERI will work together to accelerate the development of new treatments for eye diseases and cancer while enhancing production methods and technologies. This collaboration aims to leverage their combined expertise in manufacturing and scientific advancements within Singapore's biotech sector.The partnership is expected to lead to significant advancements in gene therapy, offering new treatment options for previously difficult-to-treat ophthalmic conditions and potentially improving patient outcomes in oncology. Source: ringtx.com.

Ring Therapeutics宣布与科学技术研究机构（A*STAR）和新加坡眼科研究所（SERI）建立战略合作伙伴关系。这些合作旨在加强研发工作，加强该地区的生物医学科学生态系统。这些伙伴关系将支持Ring Therapeutics平台的各个方面，包括专注于表征用于眼科和肿瘤学的新无瘤病毒基因组的早期发现计划。此外，通过测试不同治疗领域的创新有效载荷并改进其下一代制造工艺的性能，这些合作将有助于扩大公司的适应症组合。A*STAR和SERI将共同努力，加快眼病和癌症新疗法的开发，同时改进生产方法和技术。此次合作旨在利用他们在新加坡生物技术领域制造和科学进步方面的综合专业知识。。来源：ringtx.com。